IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Immutep Limited due to alleged violations of securities laws following the discontinuation of a key clinical trial, which led to a significant drop in the company's stock price [1][2]. Group 1: Investigation Details - The investigation focuses on whether Immutep issued false or misleading statements or failed to disclose important information to investors [2]. - On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa due to a planned interim futility analysis [2]. - Following this announcement, Immutep's American Depositary Receipts (ADRs) fell by more than 82.4% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights free of charge [3].